Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA; Division of Gerontology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA,02215, USA.
Division of Translational Therapeutics, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA; Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 02215, USA; Broad Institute of Harvard and MIT, Cambridge, MA, 02142, USA.
Prog Neurobiol. 2021 Aug;203:102072. doi: 10.1016/j.pneurobio.2021.102072. Epub 2021 May 9.
Traumatic brain injury (TBI) is the leading cause of mortality and disability in young people and may lead to the development of progressive neurodegeneration, such as that observed in chronic traumatic encephalopathy. We have recently found that the conformation-specific cis phosphorylated form of tau (cis P-tau) is a major early driver of neurodegeneration after TBI. However, not much is known about how cis P-tau is regulated in TBI. In this study, we demonstrated a novel critical role of death-associated protein kinase 1 (DAPK1) in regulating cis P-tau induction after TBI. We found that DAPK1 is significantly upregulated in mouse brains after TBI and subsequently promotes cis P-tau induction. Genetic deletion of DAPK1 in mice not only significantly decreases cis P-tau expression, but also effectively attenuates neuropathology development and rescues behavioral impairments after TBI. Mechanistically, DAPK1-mediated cis P-tau induction is regulated by the phosphorylation of Pin1 at Ser71, a unique prolyl isomerase known to control the conformational status of P-tau. Furthermore, pharmacological suppression of DAPK1 kinase activity dramatically decreases the levels of Pin1 phosphorylated at Ser71 as well as cis P-tau after neuronal stress. Thus, DAPK1 is a novel regulator of TBI that, in combination with its downstream targets, has a major impact on the development and/or outcome of TBI, and targeting DAPK1 might offer a potential therapeutic impact on TBI-related neurodegenerative diseases.
创伤性脑损伤 (TBI) 是年轻人死亡和残疾的主要原因,并且可能导致进行性神经退行性变,如慢性创伤性脑病中观察到的那样。我们最近发现,tau 蛋白的构象特异性顺式磷酸化形式(cis P-tau)是 TBI 后神经退行性变的主要早期驱动因素。然而,关于 TBI 中 cis P-tau 是如何被调节的,我们知之甚少。在这项研究中,我们证明了死亡相关蛋白激酶 1 (DAPK1) 在调节 TBI 后 cis P-tau 诱导中的新的关键作用。我们发现 DAPK1 在 TBI 后小鼠大脑中显著上调,随后促进 cis P-tau 诱导。在小鼠中敲除 DAPK1 不仅显著降低 cis P-tau 的表达,而且有效减轻 TBI 后的神经病理学发展和行为障碍。从机制上讲,DAPK1 介导的 cis P-tau 诱导受 Pin1 在 Ser71 处磷酸化的调节,Pin1 是一种已知控制 P-tau 构象状态的独特脯氨酰异构酶。此外,DAPK1 激酶活性的药理学抑制可显著降低神经元应激后 Pin1 在 Ser71 处磷酸化和 cis P-tau 的水平。因此,DAPK1 是 TBI 的一种新型调节剂,与下游靶标一起,对 TBI 的发展和/或结果有重大影响,靶向 DAPK1 可能对 TBI 相关神经退行性疾病具有潜在的治疗作用。